Share price movements

On March 12, MannKind Corporation (MNKD) closed at $2.09, 8.29% higher than its previous closing price, 122.34% higher than its 52-week low of $0.94, and 31.25% lower than its 52-week high of $3.04. The company’s market cap was $395.85 million, and its PS (price-to-sales) and PC (price-to-cash) multiples were 24.14x and 5.56x, respectively.

Since its fourth-quarter earnings release on February 26, MannKind stock has risen 38.41% from $1.51 on February 25 to $2.09 on March 12. On February 26, the stock closed at $1.76, 16.56% higher than its previous closing price. The company, however, missed both the consensus revenue estimate and the consensus EPS estimate by $7.47 million and $0.28, respectively, in the fourth quarter.

What Analysts Are Recommending for MannKind and Akebia in March

On March 12, Akebia Therapeutics (AKBA) closed at $8.10, 10.35% higher than its previous closing price, 55.77% higher than its 52-week low of $5.20, and 43.48% lower than its 52-week high of $14.33. The company’s market cap is $968.27 million, and its PS and PC ratios are 4.12x and 2.48x, respectively.

According to a press release, Akebia Therapeutics will be announcing its fiscal 2018 fourth-quarter and fiscal 2018 results on March 18, 2019.

Akebia Therapeutics is trading at lower PB and PC ratios than Mannkind Corporation. Both MannKind and Akebia are small-cap stocks and can prove more volatile and risky for retail investors than large-cap stocks or the broader market.

Analysts’ recommendations and target prices

The 12-month consensus recommendations for MannKind and Akebia Therapeutics are “strong buys” and “buys,” respectively.

Of the two analysts covering MannKind, one has given it a “strong buy” recommendation, while the other has given it a “buy” recommendation. The stock’s 12-month target price is $3.5, 67.46% higher than its closing price on March 12. The highest target price estimate for the company is $4, and the lowest is $3.

Of the seven analysts covering Akebia Therapeutics, one analyst has given it a “strong buy” rating, four have given it “buys,” and the remaining two have given it “holds.” Analysts’ 12-month target price is $18.88, 133.09% higher than its closing price on March 12. The highest target price estimate for the company is $30, and the lowest is $9.

Next, we’ll look at the revenue growth trajectories of MannKind Corporation and Akebia Therapeutics in greater detail.

Latest articles

19 May

Chinese Stocks are Getting Crushed

WRITTEN BY JP Gravitt

In the last month the CSI 300 is down 11.5%, much more than US indices.

JCPenney (JCP) is slated to announce its results for the first quarter of fiscal 2019, which ended on May 4, on May 21.

17 May

What to Know about the US-China Trade War

WRITTEN BY Mayur Sontakke, CFA, FRM

The key point of contention in the US-China trade dispute is the large trade deficit the United States runs against China.

On May 16, the Labor Department reported jobless claims for last week. Initial jobless claims fell by 16,000 to 212,000 for the week ended May 11.

Jeffrey Gundlach recommended investors take advantage of the volatility in interest rates at the recent Sohn Conference.

Tesla (TSLA) has fallen 4.2% as of 11:55 AM EDT on May 17. While US equity markets opened in the red today, they've recouped their losses.

172.31.16.229